Surgical Technology

Angiotech announces expansion of innovative Quill SRS product line with new choice of absorbable sutures

Published in Medical Letter on the CDC and FDA, September 2nd, 2007

Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing a new polymer line of absorbable sutures, further broadening the offering of the Quill(TM) Self-Retaining System (SRS) product line.

Angiotech is launching MONODERM(TM), a new line of Quill(TM) SRS sutures made from a rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. The Quill(TM) SRS MONODERM(TM) sutures will be available in three different diameters.

"Since the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-09-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry